GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » 5-Year Yield-on-Cost %

Danaher (Danaher) 5-Year Yield-on-Cost %

: 0.75 (As of Today)
View and export this data going back to 1986. Start your Free Trial

Danaher's yield on cost for the quarter that ended in Dec. 2023 was 0.75.


The historical rank and industry rank for Danaher's 5-Year Yield-on-Cost % or its related term are showing as below:

DHR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.33   Med: 0.87   Max: 1.63
Current: 0.75


During the past 13 years, Danaher's highest Yield on Cost was 1.63. The lowest was 0.33. And the median was 0.87.


DHR's 5-Year Yield-on-Cost % is ranked worse than
79.73% of 74 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.315 vs DHR: 0.75

Competitive Comparison

For the Diagnostics & Research subindustry, Danaher's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Danaher 5-Year Yield-on-Cost % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Danaher's 5-Year Yield-on-Cost % falls into.



Danaher 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Danaher is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Danaher  (NYSE:DHR) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Danaher 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Danaher's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Danaher (Danaher) Business Description

Address
2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, USA, 20037-1701
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in two segments--life sciences and diagnostics--after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
Executives
Jose-carlos Gutierrez-ramos officer: SVP, Chief Scientific Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Linda Filler director 2200 PENNSYLVANIA AVE NW, SUITE 800W, WASHINGTON DC 20037
Daniel Raskas officer: VP-Corporate Development 2099 PENNSYLVANIA AVENUE, NORTHWEST, WASHINGTON DC 20006
Teri List director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Joakim Weidemanis officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Walter G Lohr director DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Georgeann Couchara officer: SVP, Human Resources 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Raymond C Stevens director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew officer: EVP & Chief Financial Officer 2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Jennifer Honeycutt officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Alan G Spoon director 1150 15TH ST NW, WASHINGTON DC 20071
Rainer Blair officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Feroz Dewan director C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003
Mitchell P Rales director, officer: Chairman of Exec. Committee 11790 GLEN ROAD, POTOMAC MD 20854
Brian W Ellis officer: Senior Vice President - GC 2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037

Danaher (Danaher) Headlines

From GuruFocus

Q4 2022 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Danaher Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2021 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024